The use of bone morphogenic protein and related therapies in the management of medication-related osteonecrosis of the jaw: a scoping review

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is an uncommon adverse event of antiresorptive and antiangiogenic medications that can result in severe bony complications. Pentoxifylline and tocopherol (PENTOCO) and bone morphogenic protein (BMP) have shown promise as two therapies that could be effective in the management of MRONJ. The present paper reviews the findings of a total of 12 studies investigating the effectiveness of PENTOCO and BMP in the management of 417 patients with MRONJ. Additionally, three patient cases that were managed at our institution are discussed to supplement the findings of the review. While the available literature on the efficacy of PENTOCO and BMP use in the management of MRONJ is limited, the present study's findings support the potential effectiveness of these therapies as supplements to medical and surgical interventions currently employed.